BioLife Solutions (BLFS) Fundamental Analysis: Revenue, Earnings & Valuation

0.04 / 10

Underperform

The stock displays subpar fundamental strength (0.0/10). Encouraging metrics: Total profit (YoY growth rate %) and Net profit attributable to parent company shareholders (YoY growth rate %), whereas limitations surface in Net income-Revenue and Days sales outstanding. This profile warrants a selective stance.

Analysis Checks(7/10)

Total assets (growth rate compared to beginning of year %)

Value1.60

Score2/3

Weight102.15%

1M Return-0.74%

Days sales outstanding

Value30.74

Score0/3

Weight412.38%

1M Return-3.27%

Inventory turnover ratio

Value1.15

Score3/3

Weight-381.80%

1M Return2.68%

Net income-Revenue

Value1.13

Score0/3

Weight516.37%

1M Return-4.29%

Accounts receivable turnover ratio

Value11.71

Score0/3

Weight619.54%

1M Return-4.40%

Quick ratio

Value4.63

Score3/3

Weight-441.85%

1M Return3.57%

Total profit (YoY growth rate %)

Value-36.93

Score2/3

Weight94.08%

1M Return-0.74%

Fixed assets turnover ratio

Value4.97

Score2/3

Weight-79.16%

1M Return0.55%

Long-term debt to working capital ratio (%)

Value0.10

Score3/3

Weight-302.59%

1M Return2.31%

Net profit attributable to parent company shareholders (YoY growth rate %)

Value77.23

Score3/3

Weight-439.13%

1M Return2.84%

Is BLFS undervalued or overvalued?

BLFS scores 0.04/10 on fundamentals and holds a Premium valuation at present. Backed by its -1.27% ROE, -4.78% net margin, -205.08 P/E ratio, 2.53 P/B ratio, and 79.55% earnings growth, these metrics solidify its Underperform investment rating.